Boston Scientific Corp BSX

NYSE · EDGAR · Updated Oct 24, 2026

Boston Scientific Corp (NYSE: BSX) is a medical device company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Program	Indication	Modality	Stage
WATCHMAN / FARAPULSE / AGENT DCB / other marketed device portfolio	Cardiovascular, endoscopy, urology, neuromodulation devices	—	NA_NON_THERAPEUTIC
TIVUS Intravascular Ultrasound System (investigational)	Renal artery denervation for hypertension	—	NA_NON_THERAPEUTIC

Mar 28, 2026
met CHAMPION-AF (3,000 patients) met all primary and secondary endpoints at 36 months: non-procedural bleeding 10.9% vs 19.0% for NOACs (P<0.001, superior) and primary efficacy non-inferior (5.7% vs 4.8%, P<0.001).The primary safety endpoint was met with data demonstrating the WATCHMAN FLX device was statistically superior to NOACs (10.9% vs. 19.0%; P<0.001) for non-procedural major and clinically relevant non-major bleeding, achieving a 45% relative reduction in non-procedural bleeding risk. Filing

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export